Newman-Gage H
Northwest Tissue Center, Puget Sound Blood Center, University of Washington, Seattle 98104, USA.
J Hematother. 1996 Apr;5(2):189-93. doi: 10.1089/scd.1.1996.5.189.
There has been a long-standing interest in collection and study of fetal tissues for the purpose of understanding normal ontogeny, as well as aberrant processes in development. As the unique features and capabilities of fetal tissues have become elucidated, it is evident that fetal tissues could potentially be used to ameliorate adult degenerative diseases through transplantation. Indeed, there has been significant work surrounding the transplantation of fetal-derived hematopoietic stem cells, islet cells, and central nervous system cells. Many involved with collection and transplantation of fetal tissues seem poised on the edge of the federal regulatory playing field. This article discusses the history of regulations related to cellular and tissue-derived products and current regulatory issues facing cell and tissue banks in the United States from the tissue bank perspective and focuses on these issues as they relate to the use of cells derived from fetal tissue.
长期以来,人们一直对收集和研究胎儿组织感兴趣,目的是了解正常个体发育以及发育中的异常过程。随着胎儿组织的独特特征和能力逐渐被阐明,很明显胎儿组织有可能通过移植用于改善成人退行性疾病。事实上,围绕胎儿来源的造血干细胞、胰岛细胞和中枢神经系统细胞的移植已经开展了大量工作。许多参与胎儿组织收集和移植的人似乎处于联邦监管竞技场的边缘。本文从组织库的角度讨论了与细胞和组织衍生产品相关的监管历史以及美国细胞和组织库目前面临的监管问题,并重点关注这些问题与胎儿组织来源细胞使用的相关性。